Author Archives: Pharm Exec
By Pharm Exec | Published: September 18, 2014
By Casey McDonald. GSK will weigh in on non-communicable diseases (NCDs) in Africa with a £1m contribution and a commitment of internal R&D expertise supporting researchers from South African institutions, the company announced this month.
By Pharm Exec | Published: September 16, 2014
Merck’s Keytruda, recently approved in the US to treat patients with advanced melanoma that have stopped responding to other cancer therapies, will soon face strong competition from Bristol-Myers Squibb’s (BMS) Opdivo, an analyst from research and consulting firm GlobalData has reported.
By Pharm Exec | Published: September 15, 2014
The European Federation of Pharmaceutical Industries and Associations’ new medicines verification system will put an end to the re-sale of stolen and counterfeit drugs in the European supply chain, the organisation claims. The European Stakeholder Model (ESM) reportedly offers a cost-effective technological solution using anti-tampering device together with 2D barcoding to verify the authenticity of medicinal products. Because of loopholes […]
By Pharm Exec | Published: September 11, 2014
In this special Technology Issue of Pharm Exec Global Digest: Apple or Big Pharma: Who Will Lead in the Wearable Healthcare Device Space?; Google Glass — a Healthcare User’s Guide; UBISTART’s New Payout for Innovative Start-ups; and more… Click here to read the issue.
By Pharm Exec | Published: September 9, 2014
Three companies were crowned the Nordic region’s “shining examples of innovative life science companies” in Stockholm, Sweden, this week. Nordic Life Science Days, the region’s largest partnering conference, gave its annual Nordic Star Awards to Bone Index (Kuopio, Finland), Lytix Biopharma (Oslo, Norway) and PledPharma (Stockholm, Sweden). Bone Index was noted for its osteoporosis diagnostic, Bindex, while Lytix Biopharma […]